Streetbeat News

Products Services

ELVN

Enliven Therapeutics reported positive Phase 1 trial results for ELVN-001 in treating chronic myeloid leukemia, showing a 44% cumulative MMR rate by 24 weeks. The drug was well-tolerated with no dose reductions, indicating potential as a best-in-class treatment.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2024 | 1:42 pm

AAPL

CRWD

NVO

TSLA

Benzinga highlights key stock stories, including Apple's projected revenue from iPhones, Shiba Inu's stablecoin update, Novo Nordisk's drug benefits, and Tesla's Robotaxi event skepticism. The Dow hit a record high amid inflation progress and a Fed rate cut.

Portfolio Pulse from Michael Cohen

September 28, 2024 | 12:42 pm

BTCUSD

PEPEUSD

Arthur Hayes, co-founder of BitMEX, predicts a 'volatility supercycle' due to central bank interventions. He suggests that crypto investments will benefit from monetary easing by major economies, including the Federal Reserve, EU, China, and Japan. Hayes emphasizes Bitcoin and crypto as potential 'release valves' for excess fiat currency.

Portfolio Pulse from Khyathi Dalal

September 28, 2024 | 11:56 am

AAPL

MSFT

NVDA

Apple has withdrawn from OpenAI's funding round discussions, while Microsoft and Nvidia are still considering investments. The funding round aims to raise $6.5 to $7 billion. OpenAI is transitioning to a for-profit model, which has been controversial.

Portfolio Pulse from Ananya Gairola

September 28, 2024 | 6:52 am

HITI

High Tide Inc. (NASDAQ:HITI) ranks 87th on Canada's Top Growing Companies list for 2024, with a three-year revenue growth of 486%. The company continues to expand its retail presence in Canada and plans international expansion into Germany and the US.

Portfolio Pulse from Rolando García

September 27, 2024 | 11:32 pm

JNJ

Johnson & Johnson's CARVYKTI, a cell therapy, has shown a 45% reduction in the risk of death for multiple myeloma patients in the CARTITUDE-4 study, making it the first therapy to significantly extend overall survival compared to standard treatments.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:33 pm

NYXH

Nyxoah presented data from its DREAM pivotal study at the International Surgical Sleep Society 2024, showing a 71% median reduction in Apnea-Hypopnea Index for patients with Obstructive Sleep Apnea. The study also reported significant improvements in quality-of-life outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:32 pm

PSTX

Poseida Therapeutics has reported interim results from its Phase 1 trial of the allogeneic CAR-T therapy P-BCMA-ALLO1, showing a 91% overall response rate (ORR). This promising result could have positive implications for the company's future prospects in the CAR-T therapy market.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:32 pm

EWZ

GOOG

GOOGL

Google has updated its Google Ads policy to allow online sports betting and gambling ads in Brazil starting after September 30. Advertisers must show they have requested authorization from the Brazilian Ministry of Finance.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:28 pm

SGML

Sigma Lithium marked its first production year and announced plans to expand its industrial capacity to 125,000 t/y LCE by 2026. The company targets $420M EBITDA by 2025 and $700M by 2027, supported by capital investments and a partnership with BNDES. Sigma was recognized by Nasdaq for its climate leadership.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:21 pm